Now Playing
Opinion|Videos|December 19, 2023
AL Amyloidosis: Background, Patient Profile, and Staging
Author(s)Jeffrey Zonder, MD, Shaji Kumar, MD
Expert oncologists Dr. Jeffrey Zonder and Dr. Shaji Kumar discuss AL amyloidosis background, typical patient profiles, and disease staging and risk stratification.
Advertisement
Advertisement
Related to this article
The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.
The FDA approved selpercatinib for RET fusion–positive advanced solid tumors.
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
A triplet combination regimen led to high remission rates in patients with blastic plasmacytoid dendritic cell neoplasm.
The CDH17-targeting antibody-drug conjugate received the designation for previously treated advanced unresectable or metastatic colorectal cancer.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Ruxolitinib plus extracorporeal photopheresis drove responses in steroid-refractory or -dependent chronic graft-vs-host disease.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
2
FDA Awards Traditional Approval to Selpercatinib for RET+ Advanced Solid Tumors
3
FDA Grants Fast Track Designation to SOT109 in Advanced Colorectal Cancer
4
Research Rewind: Phase 3 Breast Cancer Data Highlights From Q2 2026
5